VNRX: שווי חברה לרווח נקי volition.com

VolitionRx Limited (VNRX) develops automated stations for epigenetic blood studies, minimizing the risk of human error. This price chart illustrates the asset's dynamics, with a value of -0.20. The brand is valued by the global community for its affordable early pathology detection methods. The company is currently implementing Nu.Q systems, where artificial intelligence continuously processes and labels biomaterials.

VolitionRx Limited (VNRX) monetizes Nu.Q epigenetic tests through the B2B veterinary segment and expects expansion into human medicine following FDA rulings. The P/E ratio correlates the business's market value with its net income, allowing investors to determine the asset's degree of overvaluation or bankruptcy risk, which the company's monthly P/E trend clearly reflects by revealing hidden vulnerabilities to regulatory shocks.